FDA-approved1,2Evidence: Large human trialsSkin · Infections

Daptomycin1

Also called Cubicin, Cubicin RF1,2

Key takeaway

Daptomycin is a cyclic lipopeptide antibiotic, a ring-shaped peptide with a fatty side chain, made by fermentation of the bacterium Streptomyces roseosporus. It is the active ingredient in Cubicin and Cubicin RF.1,2 FDA first approved it in 2003. The label covers complicated skin infections in adults and children aged 1 to 17, and Staphylococcus aureus bloodstream infections, including right-sided heart valve infection in adults.1,2 In two randomized trials in adults with complicated skin infections, cure rates were similar to standard comparator antibiotics. The label states that it is not indicated for pneumonia.1

Daptomycin at a glance

What it isA cyclic lipopeptide antibacterial that binds bacterial cell membranes and collapses their electrical potential, which kills the bacteria, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists NDA 021572 with an original approval date of September 12, 2003. The cited label has no boxed warning.1,2
Human evidenceTwo randomized, investigator-blinded trials in about 1,092 adults with complicated skin infections and a randomized, open-label trial in 246 adults with S. aureus bloodstream infection, described in the label.1
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is daptomycin?

Daptomycin is a cyclic lipopeptide antibacterial agent derived from the fermentation of Streptomyces roseosporus, according to the label.1

Drugs@FDA lists Cubicin and Cubicin RF under application NDA 021572.2

How does daptomycin work?

The label states that daptomycin binds bacterial cell membranes and rapidly depolarizes them; the loss of membrane potential stops DNA, RNA and protein synthesis and kills the bacteria.1

What do human studies show?

In Study 9801, clinical success in all randomized patients was 62.5% with daptomycin and 60.9% with comparators; Study 9901 was a second randomized trial of the same design, according to the label.1

In a randomized, open-label trial of 246 adults with S. aureus bloodstream infection, success judged by a blinded committee six weeks after treatment was 44.2% with daptomycin and 41.7% with comparators, according to the label.1

The label reports that success was lower in adults with moderately reduced kidney function, and that outcomes in left-sided heart valve infection were poor.1

What the evidence base contains

  • Large randomized human trial Study 9801: a randomized, multinational, investigator-blinded trial in 530 adults with complicated skin and skin structure infections, comparing daptomycin with standard antibiotics, described in the label.1
  • Large randomized human trial Study 9901: a randomized, multinational, investigator-blinded trial in 562 adults with complicated skin and skin structure infections, described in the label.1
  • Controlled human trial A randomized, controlled, open-label trial in 246 adults with S. aureus bloodstream infection, described in the label.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is daptomycin FDA-approved?

Yes. Drugs@FDA lists application NDA 021572, for Cubicin and Cubicin RF, with an original approval date of September 12, 2003.2

The Cubicin RF label cited here (DailyMed SPL version 22, published June 20, 2025) states that it is indicated for complicated skin and skin structure infections in adults and children aged 1 to 17, and for S. aureus bloodstream infections in adults, including right-sided infective endocarditis, and in children aged 1 to 17.1

The label has no boxed warning. It states that daptomycin is not indicated for pneumonia or for left-sided S. aureus endocarditis, and its warnings include muscle damage, eosinophilic pneumonia, severe drug reactions and nerve damage.1

Timeline

  1. FDA approves daptomycin under NDA 021572, according to Drugs@FDA.2
  2. DailyMed publishes the Cubicin RF label version cited on this page.1

What is still unknown?

Its effect in left-sided heart valve infection, for which the label states its trial data were limited and outcomes poor.1

Its safety in infants under 12 months, in whom the label advises against use because of possible effects on muscles and nerves.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Daptomycin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Daptomycin are a bounded selection, not every registration or paper about Daptomycin. For the years before Daptomycin was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Daptomycin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Daptomycin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Cubicin RF for skin infections and S. aureus bloodstream infections. Randomized trials described in the label found success rates similar to standard comparator antibiotics. The label states that it is not indicated for pneumonia.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Daptomycin?

FDA-approved as Cubicin RF for skin infections and S. aureus bloodstream infections. Randomized trials described in the label found success rates similar to standard comparator antibiotics. The label states that it is not indicated for pneumonia.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
17
Drugs@FDA applications
32

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 15, 2026

    Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial.↗Source date November 9, 2026
  2. Literature metadata · added November 15, 2026

    Daptomycin for enterococcal bloodstream infections and endocarditis: reconciling clinical evidence, susceptibility testing, and regulatory frameworks.↗Source date October 13, 2026
  3. Literature metadata · added November 15, 2026

    Clinical Pharmacokinetics of Daptomycin.↗Source date October 10, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Daptomycin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

102Selected dated records
104Connected citations
17Populated source years2003–2026
3/4Record lanes present

Registered human studies

Trial composition

30 of 30 selected trial records include at least one phase value; 30 of 30 include a status value in the retained structured contract.

PhasesPhase 4 13Phase 3 9Phase 2 5Phase 1 2Not applicable 1
Status at observationCompleted 28Enrolling by invitation 1Recruiting 1

PubMed bibliography

Publication composition

30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 30Review 15Systematic Review 9Meta-Analysis 6Case Reports 3Clinical Trial 2Research Support, N.I.H., Extramural 2Equivalence Trial 1Randomized Controlled Trial 1Research Support, Non-U.S. Gov't 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
32
FDA Federal Register documents
10
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
102

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 102 dated records

Research hub

Explore the Daptomycin evidence record

Open all 102 records →
102Dated records
3Evidence types
102Cited public sources
17Source years

Change ledger

Recently changed for Daptomycin

Open all 102 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00093067

PeptideScanner retained ClinicalTrials.gov record NCT00093067 at 2026-11-15T22:01:45.056Z. Its registry update date was 2017-02-13, and PeptideScanner's reviewed identity mapping was daptomycin.

PeptideScanner change date
November 15, 2026
Cited source date
February 13, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00295178

PeptideScanner retained ClinicalTrials.gov record NCT00295178 at 2026-11-15T22:01:45.056Z. Its registry update date was 2017-09-07, and PeptideScanner's reviewed identity mapping was daptomycin.

PeptideScanner change date
November 15, 2026
Cited source date
September 7, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00428844

PeptideScanner retained ClinicalTrials.gov record NCT00428844 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-01-31, and PeptideScanner's reviewed identity mapping was daptomycin.

PeptideScanner change date
November 15, 2026
Cited source date
January 31, 2018
Evidence lane
Clinical trials

Official-source collections

Source records for Daptomycin

Open the full research atlas →
PubMed30

30 with attributed title, venue, publication-date, and type metadata.

  1. Daptomycin for enterococcal bloodstream infections and endocarditis: reconciling clinical evidence, susceptibility testing, and regulatory frameworks.The Lancet. Infectious diseases · 2026 10 13
  2. Analytical Methods for Daptomycin Determination: Applications in Biological Matrices and Pharmaceutical Formulations.Critical reviews in analytical chemistry · 2025 12 01
  3. Molecular mechanisms of resistance and tolerance of Staphylococcus aureus to daptomycin.International journal of antimicrobial agents · 2025 11 24
Explore all selected literature →
ClinicalTrials.gov30

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT03138733Registry update October 7, 2026 · completed at observation
  2. NCT07148960Registry update September 17, 2026 · current at observation
  3. NCT05137119Registry update May 6, 2026 · current at observation
Explore all selected trial records →Explore all public record history →
Drugs@FDA32

Original-submission application metadata connected by exact reviewed active-ingredient names.

  1. NDA217630Full FDA chronology · original submission status AP 2024-11-21
  2. ANDA217215Full FDA chronology · original submission status AP 2024-08-29
  3. ANDA213396Full FDA chronology · original submission status AP 2024-08-01
  4. ANDA213966Full FDA chronology · original submission status AP 2023-08-07
  5. NDA217415Full FDA chronology · original submission status AP 2023-01-30
Explore all selected FDA applications →Explore 0 dated submissions and 0 documents for Daptomycin →

Evidence types

Coverage by source year

Selected records span September 12, 2003 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
Dated updates connected to this profile · 102

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial.↗

    PubMed lists PMID 32725216 in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Equivalence Trial, with publication-date metadata of 2021-05-04 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Daptomycin for enterococcal bloodstream infections and endocarditis: reconciling clinical evidence, susceptibility testing, and regulatory frameworks.↗

    PubMed lists PMID 42869054 in The Lancet. Infectious diseases as Journal Article, Review, with publication-date metadata of 2026-10-13 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Clinical Pharmacokinetics of Daptomycin.↗

    PubMed lists PMID 33313994 in Clinical pharmacokinetics as Journal Article, Review, with publication-date metadata of 2020-12-14 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    The Antibiotic Peptide Daptomycin Functions by Reorganizing the Membrane.↗

    PubMed lists PMID 33620544 in The Journal of membrane biology as Journal Article, Review, with publication-date metadata of 2021-02-23 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT03138733↗

    PeptideScanner retained ClinicalTrials.gov record NCT03138733 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT07148960↗

    PeptideScanner retained ClinicalTrials.gov record NCT07148960 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-09-17, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT05137119↗

    PeptideScanner retained ClinicalTrials.gov record NCT05137119 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT04983901↗

    PeptideScanner retained ClinicalTrials.gov record NCT04983901 at 2026-11-15T22:01:45.056Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was daptomycin.↗

  9. Literature metadata

    Molecular mechanisms of resistance and tolerance of Staphylococcus aureus to daptomycin.↗

    PubMed lists PMID 41297715 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2025-11-24 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Analytical Methods for Daptomycin Determination: Applications in Biological Matrices and Pharmaceutical Formulations.↗

    PubMed lists PMID 41321327 in Critical reviews in analytical chemistry as Journal Article, Review, with publication-date metadata of 2025-12-01 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Daptomycin eosinophilic pneumonia, a systematic review of the literature and case series.↗

    PubMed lists PMID 39028390 in Infection as Systematic Review, Journal Article, Case Reports, with publication-date metadata of 2024-07-19 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Use of Daptomycin to Manage Severe MRSA Infections in Humans.↗

    PubMed lists PMID 40558207 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2025-06-18 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    CUBICIN RF (daptomycin) injection, powder, lyophilized, for solution · SPL version 22 · published 2025-06-20 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: CUBICIN and CUBICIN RF (daptomycin), NDA 021572 · original approval September 12, 2003 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026